Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
No. The Eversense E3 Sensor is only compatible with the Eversense E3 Smart Transmitter. The Eversense E3 Smart Transmitter is only compatible with the Eversense E3 Sensor.
No, your sensor will continue to work for the remainder of the time (up to 3 months(2))
(2)Indicated for up to 90 days
If you have your mobile device set to Do No Disturb, you will not hear any notifications from the Eversense® App unless you have turned on the Low Glucose Override. Mobile device DND does NOT turn off transmitter on-body vibes.
We strongly recommend that users do not activate Do Not Disturb on their mobile device unless they have the “Low Glucose Override” setting ON.
Low Glucose Override, when turned ON, will sound the Low and Out of Range Low Glucose alerts at the mobile device’s maximum volume even when the mobile device is set to Do Not Disturb.
Some apps and settings such as Driving Mode may automatically enable Do Not Disturb. Please refer to your mobile device instructions for more information
You can also add Notes to each of the Event types if there is additional information you would like to include.
NOTE: The Notes that are added in the App are not viewable in DMS. The notes are only available in the App.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0060